Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$18.4M | -$46.2M | -$75.8M | -$120M | -$119M | -$105M | -$44.6M | -$58.0M | -$84.0M |
| Net income | -$18.6M | -$46.4M | -$73.0M | -$120M | -$119M | -$106M | -$42.8M | -$58.0M | -$74.2M |
| EPS (diluted) | -$8.38 | -$3.62 | -$2.66 | -$3.31 | -$2.78 | -$2.42 | -$33.76 | -$6.83 | -$4.05 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.4M | -$37.6M | -$67.7M | -$98.8M | -$98.0M | -$97.2M | -$40.7M | -$59.1M | -$60.1M |
| Capital expenditures | $383K | $1.83M | $1.58M | $1.18M | $2.46M | $267K | $279K | $156K | $208K |
| Free cash flow | -$16.8M | -$39.5M | -$69.3M | -$100.0M | -$100M | -$97.5M | -$41.0M | -$59.2M | -$60.3M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.96M | $126M | $187M | $260M | $190M | $92.6M | $28.8M | $141M | $254M |
| Total assets | $7.02M | $133M | $201M | $271M | $204M | $104M | $39.4M | $153M | $261M |
| Total liabilities | $3.66M | $11.3M | $14.5M | $16.9M | $34.4M | $28.6M | $43.4M | $12.1M | $9.71M |
| Long-term debt | — | — | — | — | $15.0M | $15.0M | — | — | — |
| Shareholders' equity | -$23.1M | $122M | $186M | $254M | $169M | -$45.7M | -$84.6M | $141M | $251M |
| Retained earnings | -$23.5M | -$71.7M | -$145M | -$264M | -$384M | -$489M | -$90.6M | -$149M | -$223M |
| Shares (wtd avg diluted) | 2.31M | 23.8M | 31.6M | 43.7M | 42.9B | 43.7M | 1.27M | 8.49M | 18.3M |
Every figure is extracted from Tectonic Therapeutic, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.